Significant Phase 2 Findings from KAHR Bio on DSP107 for Colorectal Cancer Therapy KAHR Bio announced impressive Phase 2 results for DSP107, showing extended survival in colorectal cancer by combining it with atezolizumab therapy.

Significant Phase 2 Findings from KAHR Bio on DSP107 for Colorectal Cancer Therapy #Israel #Colorectal_Cancer #DSP107 #KAHR_Bio #Modi'in

KAHR Bio's DSP107 Shows Promising Phase 2 Results in Colorectal Cancer Treatment via Anti-PD-L1 Combination Therapy KAHR Bio's innovative Phase 2 trial reveals compelling results for DSP107 combined with anti-PD-L1 treatment in colorectal cancer, enhancing survival rates beautifully.

KAHR Bio's DSP107 Shows Promising Phase 2 Results in Colorectal Cancer Treatment via Anti-PD-L1 Combination Therapy #Israel #Colorectal_Cancer #DSP107 #KAHR_Bio #Modi'in

KAHR Bio to Present Game-Changing Results of DSP107 in Colorectal Cancer at ASCO 2025 KAHR Bio is set to unveil promising findings on DSP107 combined with atezolizumab for colorectal cancer patients at the prestigious ASCO meeting in 2025.

KAHR Bio to Present Game-Changing Results of DSP107 in Colorectal Cancer at ASCO 2025 #United_States #Chicago #biotech #KAHR #DSP107